2020
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
Longo D, Shoda L, Howell B, Coric V, Berman R, Qureshi I. Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym. Toxicological Sciences 2020, 175: 292-300. PMID: 32040174, PMCID: PMC7253195, DOI: 10.1093/toxsci/kfaa019.Peer-Reviewed Original ResearchConceptsOral tabletsALT elevationLiver toxicityClinical dataFirst-pass liver metabolismLiver function test parametersFirst-pass hepatic metabolismLiver toxicity riskAlanine transaminase levelsRelative risk reductionLower overall doseAmyotrophic lateral sclerosisALT levelsTransaminase levelsLiver exposureSublingual formulationHepatic metabolismLateral sclerosisRiluzoleLiver metabolismULNInterindividual variabilityOverall doseHepatotoxicity potentialOxidative stress
2005
Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder.
Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. The Journal Of Clinical Psychiatry 2005, 66: 1492-3. PMID: 16420092, DOI: 10.4088/jcp.v66n1121d.Peer-Reviewed Original ResearchRiluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial
Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial. Biological Psychiatry 2005, 58: 424-428. PMID: 15993857, DOI: 10.1016/j.biopsych.2005.04.043.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresYale-Brown Obsessive Compulsive ScaleTreatment-resistant OCD patientsAddition of riluzolePractical clinical benefitOpen-label trialGlutamate-modulating agentsSerious adverse effectsHamilton Depression InventoryAnxiety Inventory scoresObsessive Compulsive ScaleMost patientsStandard therapyGlutamatergic dysfunctionAugmentation therapyClinical benefitPrimary diagnosisStandard treatmentCorticostriatal pathwayTreatment respondersRiluzolePatientsDepression Inventory